REGENERON PHARMACEUTICALS, INC. Contract with Customer, Liability, Noncurrent in USD from Q4 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
Summary
Regeneron Pharmaceuticals, Inc. quarterly Contract with Customer, Liability, Noncurrent history and growth rate from Q4 2017 to Q3 2025.
  • Regeneron Pharmaceuticals, Inc. Contract with Customer, Liability, Noncurrent for the quarter ending September 30, 2025 was $219M, a 5.69% increase year-over-year.
Contract with Customer, Liability, Noncurrent, Quarterly (USD)
Contract with Customer, Liability, Noncurrent, YoY Quarterly Growth (%)

REGENERON PHARMACEUTICALS, INC. Quarterly Contract with Customer, Liability, Noncurrent (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $219M +$11.8M +5.69% Sep 30, 2025 10-Q 2025-10-28
Q2 2025 $206M +$700K +0.34% Jun 30, 2025 10-Q 2025-08-01
Q1 2025 $212M +$26M +14% Mar 31, 2025 10-Q 2025-04-29
Q4 2024 $186M +$59M +46.6% Dec 31, 2024 10-Q 2025-10-28
Q3 2024 $207M +$82.1M +65.5% Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $206M +$89.4M +76.9% Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $186M +$100M +117% Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $127M +$56.9M +81.5% Dec 31, 2023 10-K 2025-02-05
Q3 2023 $125M +$65.2M +108% Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $116M +$57.5M +98% Jun 30, 2023 10-Q 2023-08-03
Q1 2023 $85.5M +$52M +155% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 $69.8M -$3.5M -4.78% Dec 31, 2022 10-K 2024-02-05
Q3 2022 $60.1M +$3.6M +6.37% Sep 30, 2022 10-Q 2022-11-03
Q2 2022 $58.7M +$8M +15.8% Jun 30, 2022 10-Q 2022-08-03
Q1 2022 $33.5M +$6.5M +24.1% Mar 31, 2022 10-Q 2022-05-04
Q4 2021 $73.3M +$15.5M +26.8% Dec 31, 2021 10-K 2023-02-06
Q3 2021 $56.5M Sep 30, 2021 10-Q 2021-11-04
Q2 2021 $50.7M Jun 30, 2021 10-Q 2021-08-05
Q1 2021 $27M Mar 31, 2021 10-Q 2021-05-06
Q4 2020 $57.8M -$561M -90.7% Dec 31, 2020 10-K 2022-02-07
Q4 2019 $619M +$155M +33.3% Dec 31, 2019 10-K 2020-02-07
Q4 2018 $464M -$165M -26.2% Dec 31, 2018 10-K 2020-02-07
Q4 2017 $629M Dec 31, 2017 10-K 2019-02-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.